Company intelligence / Profile preview

Cefaly Technology

Ownership: Private
Employees: ~29
Development stage: Commercial

Overview

Clinical studies have shown that the CEFALY device significantly reduces headache days and acute medication use in chronic migraine patients. The device has demonstrated safety and efficacy comparable to standard drug treatments but with fewer side effects. It has received FDA clearance for both acute and preventive migraine treatment[1][2][6].

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation device (external trigeminal nerve stimulation)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Cefaly Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cefaly Technology.

Explore the full profile